New drug MK-1200 tested in patients with advanced cancers
NCT ID NCT06242691
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find a safe dose and see if the drug can shrink tumors. Participants had already tried other treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Digestive Oncology ( Site 0401)
Beijing, Beijing Municipality, 100142, China
-
Bradfordhill-Clinical Area ( Site 0301)
Santiago, Region M. de Santiago, 8420383, Chile
-
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)
Huai'an, Jiangsu, 223300, China
-
Fujian Cancer Hospital-oncology department ( Site 0409)
Fuzhou, Fujian, 350000, China
-
Hadassah Medical Center ( Site 0604)
Jerusalem, 9112001, Israel
-
Rabin Medical Center-Oncology ( Site 0603)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology Division ( Site 0602)
Haifa, 3109601, Israel
-
START Midwest ( Site 0014)
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region ( Site 0015)
West Valley City, Utah, 84119, United States
-
Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)
Seoul, 06351, South Korea
-
Sheba Medical Center ( Site 0605)
Ramat Gan, 5265601, Israel
-
Sourasky Medical Center ( Site 0601)
Tel Aviv, 6423906, Israel
-
South Texas Accelerated Research Therapeutics (START) ( Site 0005)
San Antonio, Texas, 78229, United States
-
The Alfred Hospital ( Site 0103)
Melbourne, Victoria, 3004, Australia
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
Louisville, Kentucky, 40202, United States
-
University of Virginia Health System-Hematology-Oncology ( Site 0009)
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.